Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
5.61
+0.14 (2.56%)
At close: Dec 20, 2024, 4:00 PM
5.59
-0.02 (-0.36%)
After-hours: Dec 20, 2024, 4:44 PM EST
Tenax Therapeutics Employees
As of December 31, 2023, Tenax Therapeutics had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,426,764
Market Cap
19.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Retractable Technologies | 151 |
| Senti Biosciences | 48 |
| HCW Biologics | 45 |
| IN8bio | 31 |
| Bullfrog AI | 11 |
| Alterity Therapeutics | 10 |
| CervoMed | 8 |
TENX News
- 5 weeks ago - Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 7 weeks ago - Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 4 months ago - Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement - GlobeNewsWire
- 7 months ago - Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 8 months ago - Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - GlobeNewsWire
- 9 months ago - Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” - GlobeNewsWire
- 9 months ago - Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results - GlobeNewsWire